Study of The Prevalence of Carbapenems Resistance In Clinically Isolated Enterobacteriaceae
Main Article Content
Abstract
According to the World Health Organization, antibiotic resistance is a growing global challenge. It complicates the selection of appropriate experimental treatments for infectious diseases, leading to increased medical costs and mortality rates. This study aimed to estimate the prevalence of carbapenem-resistant Enterobacteriaceae (CRERA) to aid in the early detection of resistant strains, limit their spread, and select appropriate treatments for patients suspected of infection. Forty-five isolates were collected from clinical samples at Al-Kindi Teaching Hospital in Baghdad between January and December 2025. Bacterial identification results showed that Klebsiella pneumoniae was the most common isolate (33%), followed by Escherichia coli (29%), Proteus mirabilis (20%), and Enterobacter cloacae (11%). The results of the susceptibility testing showed that the majority of the studied bacterial isolates exhibited high resistance to the tested antibiotics. These high resistance rates indicate a widespread prevalence of multiple resistance mechanisms among the studied isolates. Complete resistance (100%) was recorded for imipenem, meropenem, and amoxicillin/clavulanic acid, while resistance rates of 99% and 98% were recorded for ertapenem and ceftriaxone, respectively. Phenotypic testing for carbapenemases using the modified carbapenem inactivation method (mCIM) revealed that 35 out of 45 isolates (78%) produced carbapenemases, with the highest production rates observed in Klebsiella pneumoniae (88%). This reflects the clear prevalence of carbapenemases among Enterobacteriaceae in the studied bacterial isolates.
Article Details

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.